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Background The epidemiology of atrial fibrillation (AF) without comorbidities, known as ‘lone AF’, is uncertain.
Although it has been considered a benign condition, we hypothesized that it confers a worse prognosis compared with a
matched sample without AF.
Methods We described the proportion of AF without comorbidities (clinical, subclinical cardiovascular disease and
triggers) among the entire AF sample in Framingham Heart Study (FHS). We compared AF without comorbidities with typical
AF, and age-, sex- and cohort-matched individuals without AF, using Cox proportional hazards analysis in relation to
combined cardiovascular events (stroke, heart failure, myocardial infarction), and mortality.
Results Of 10,311 FHS participants, 1,961 were diagnosed with incident AF, among which 173 individuals had AF
without comorbidities (47% women, mean age 71±12 years). AF without comorbidities had a prevalence of 1.7% of the entire
cohort, and an annual incidence of 0.5 per 1000 person-years. During a median follow-up of 9.7 years after initial AF, 137
individuals with AF without comorbidities (79.2%) died and 141 individuals developed cardiovascular events (81.5%). AF
without comorbidities had significantly lower mortality (HR 0.67, 95%CI 0.55-0.81, P b .001) and total cardiovascular events
(HR 0.66, 95% CI 0.55-0.80, P b .001) compared with typical AF. However, mortality (HR1.43, 95% CI 1.18-1.75, P b .001)
and risk of total cardiovascular events (HR 1.73, 95% CI 1.39-2.16, P b .001) were higher than age-, sex-, and cohort-
matched individuals without AF.
Conclusions The risk of cardiovascular outcomes and mortality among individuals with AF without comorbidities is lower
than typical AF, but is significantly elevated compared with matched individuals without AF. (Am Heart J 2016;177:138-44.)
‘Lone atrial fibrillation (AF)’ was initially described in
the 1950s as AF in the absence of other known risk factors
such as structural heart disease, thyrotoxicosis, and
hypertension.1,2 More recently, ‘lone AF’ has been
defined as AF with no clinical or echocardiographic
evidence of concomitant cardiovascular, or pulmonary
conditions in younger adults.3 However, guidelines do
not specify which concomitant conditions have to be
excluded to classify ‘lone AF’ including the age criteria. In
part due to the lack of cohesive definition of this
condition, the natural history of ‘lone AF’ has remained
unclear. ‘Lone AF’ was initially thought to be a benign
condition especially when it was diagnosed at a younger
age or was paroxysmal.3,4 However, a community-based
cohort study suggested increased risk for mortality and
thromboembolism in people with ‘lone AF’ compared
with individuals without AF.5
Recently a plethora of emerging associations with AF
has been revealed with improved methods of imaging,
and better understanding of the pathophysiology of AF.6
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Clinical Investigation
More stringent criteria have been suggested for the
definition of ‘lone AF’. Some investigators even question
its existence.7 Hence, for the present investigation we
use the terminology ‘AFwithout comorbidities’ to refer to
‘lone AF’.
In a large community-based sample, we sought to
investigate the epidemiology and AF-related adverse
outcomes (such as stroke, heart failure, myocardial
infarction, and all-cause mortality) in individuals with
AF without recognized comorbidities. We compared this
group with typical AF patients who have comorbidities,
and also to an age- and sex-matched group of individuals
without AF, respectively. We hypothesized that the risk
of cardiovascular outcomes in AF without comorbidities
would be less than typical AF but greater than the
matched group without AF.
Methods
Study sample
The Framingham Heart Study was initiated in 1948 to
examine cardiovascular disease and its risk factors. The
details of enrollment and participation have been
described previously. Briefly, the study enrolled
community-dwelling individuals, termed the Original
cohort (N = 5209), who underwent examinations every
2 years.8 In 1971, the study enrolled the Original cohort’s
children and their spouses into the Offspring cohort (n =
5124), who had examinations approximately every 4 or 8
years.9 During each Heart Study visit, a research
physician and technicians collected data for cardiovascu-
lar risk factors and interim cardiovascular events.
Individuals provided written informed consent at each
examination. The Boston University Medical Center
Institutional Review Board approved the study protocols
at each examination cycle.
Atrial fibrillation ascertainment
Atrial fibrillation was diagnosed by the presence of AF
or atrial flutter on electrocardiogram or Holter monitor-
ing obtained during a Framingham Heart Study clinic
visit, an external clinician visit, hospitalization, or review
of medical records. Two Framingham Heart Study
cardiologists adjudicated incident AF events.
Definition of atrial fibrillation without comorbidities
Atrial fibrillation without comorbidities was defined as
AF in the absence of traditional risk factors including
history of coronary heart disease, heart failure, valvular
disease by physical exam (≥3/6 systolic murmur or any
diastolic murmur) or echocardiographic data if available
(≥moderate mitral, tricuspid or aortic regurgitation, any
mitral stenosis, and ≥mild aortic stenosis), cardiomyop-
athy (left ventricular ejection fraction b50%), treated
hypertension or blood pressure ≥140 mmHg systolic or
≥90 mmHg diastolic, diabetes mellitus (history of
diabetes, use of hypoglycemic agents or insulin), prior
stroke or transient ischemic attack, ECG evidence of left
ventricular hypertrophy, and hyperthyroidism (thyroid
stimulating hormoneb0.5 μU/L). In addition, we used
more stringent criteria incorporating additional risk
factors and acute precipitants to define AF without
comorbidities after excluding class II or higher obesity
(body mass index ≥35 kg/m2), first-degree atrioventric-
ular block (PR interval≥200 ms), cardiac and non-cardiac
surgery, coronary interventions, acute medical illness,
concurrent infection, acute alcohol intoxication, chronic
obstructive pulmonary disease, and intense exercise (3
times a week ≥1-hour workout, during the year before
initial AF).10 We performed a rigorous chart review
searching both traditional and additional risk factors and
extracted covariates from the latest examination prior to
the onset of AF.
Follow-up and cardiovascular outcomes
We followed participants from the AF onset until the
earliest AF-related outcome such as stroke, heart failure,
myocardial infarction, or all-cause mortality, and last
contact. Stroke, heart failure, and myocardial infarction
adjudication at the Framingham Heart Study have been
described previously.11,12
Statistical analysis
We described the proportion and clinical outcomes of
AF individuals without recognized comorbidities with
and without the age criteria (b60 years) among the entire
AF sample. We used Cox proportional hazards regression
analysis to estimate the association of AF without
comorbidities with the risk of combined and individual
cardiovascular events including stroke, heart failure,
myocardial infarction, and all-cause mortality in compar-
ison with individuals with typical AF and without AF. Due
to a small sample size, this analysis was performed on AF
without recognized comorbidities without using the age
criteria. When evaluating total incident events, the
earliest developed cardiovascular event was counted.
We utilized the matched cohort design to generate the
group without AF for this purpose, ie, for each AF case
without comorbidities, 10 referents free of AF and
prevalent cardiovascular events at the time of the case’s
diagnosis were identified and matched to the case by age
(±1 year), sex, and cohort status (original vs. offspring at
enrollment) only for a more “realistic” interpretation of
the outcome. We evaluated the factors associated with
AF-related clinical outcomes among AF individuals
without comorbidities in stratified proportional hazards
models with matching sets within the group as strata.
Age-, sex- and cohort-adjusted estimates of the cumulative
incidence of cardiovascular events were calculated
using the corrected group prognosis method for individ-
uals with AF without comorbidities, typical AF, and
without AF.13,14
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We considered a 2-sided P b .05 as statistically
significant. SAS version 9.3 (Copyright, SAS Institute
Inc, Cary, NC) was used for all analyses.
The authors are solely responsible for the design and
conduct of this study, all study analyses, the drafting and
editing of the paper and its final contents.
Results
Among 10,311 individuals with no known prevalent AF
at enrollment, we observed 1,961 individuals with AF
(49% women, mean age 71±12 years) over 33±12 years of
follow-up, among which we observed 173 individuals
with AF without recognized comorbidities. We illustrated
the process of exclusion among individuals with AF with
both hierarchical and non-hierarchical prevalence of
individual cardiovascular conditions at time of diagnosis
(Supplementary Table 1). The individual characteristics
of each group are summarized in Table I. AF without
comorbidities comprised 1.7% of the entire cohort. The
annual incidence of AF without clinically recognized
comorbidities was 0.5 per 1000 person-years. Supple-
mentary Table 2 illustrates the percentage of AF without
comorbidities according to age, sex, and date of AF
diagnosis. Thirty-one among 173 individuals with AF
without comorbidities (18%) were below 60 years of age
as demonstrated in Supplementary Table 3 and annual
incidence in this group was 0.1 per 1000 person-years.
The median follow-up from the AF onset until the first
cardiovascular outcome was 9.7 years (interquartile range
5.2, 17.4). Rates of individual and combined cardiovascular
events after an initial episode of AF during follow-up among
AF individuals without comorbidities (with and without age
criteria) vs. typical AF vs. matched cohort were described in
Table II and Supplementary Table 4. During a follow-up
period, 137 individuals with AF without comorbidities
(79.2%) died and 141 individuals developed cardiovascular
events (81.5%). Among the group younger than 60 years
with AF without comorbidities, 19 individuals died (61.3%)
and 20 had cardiovascular events (64.5%). Table III
Table I. Individual characteristics
Characteristics
AF without
comorbidities (n = 173)
Typical AF without
prevalent CVD (n = 1031)
Matched cohort without
prevalent CVD (n = 1700)
Age⁎, yrs 70.5 ± 11.6 75.0 ± 11.2 70.0 ± 11.3
Age⁎ b60 yrs 31 (18%) 85 (8%) 354 (19%)
Men 92 (53%) 509 (49%) 983 (53%)
Systolic blood pressure (mmHg) 128 ± 15 142 ± 23 135 ± 21
Hypertension treatment - 489 (48%) 280 (21%)
Myocardial infarction - - -
Valvular heart disease (auscultation) - 110 (12%) 26 (2%)
Heart failure - - -
Diabetes mellitus - 114 (13%) 70 (4%)
CABG or PTCA - 83 (9%) 21 (1%)
Previous stroke - - -
Body mass index (kg/m2) 26.0 ± 3.8 27.9 ± 5.5 26.4 ± 4.1
ECG PR interval (ms) 162 ± 20 178 ± 41 166 ± 23
Data was presented as counts (percentages) or mean±SD.
– signifies that the feature was an exclusion criteria.
Abbreviations: AF, Atrial fibrillation; CABG, coronary artery bypass grafting; PTCA, percutaneous transluminal coronary angioplasty; ECG, electrocardiogram.
⁎Age was at the beginning of the follow-up period the age when first AF occurred.
Table II. Development of cardiovascular events in 10 years after initial AF
Cardiovascular events
AF without comorbidities (n = 173) Typical AF (n = 1031) Matched cohort (n = 1700)
Event (n)
Incidence
(per 1000 person-years) Event (n)
Incidence
(per 1000 person-years) Event (n)
Incidence
(per 1000 person-years)
Stroke 10 6 60 9 85 4
Heart failure 33 21 245 42 189 9
Myocardial infarction 14 8 69 11 175 9
All-cause mortality 137 77 792 118 1226 59
Total cardiovascular events⁎ 141 94 828 151 1253 65
Typical AFs with prevalent cardiovascular events were excluded from the analysis (e.g. total # typical AF=1664, # typical AF with prevalent events= 633). Follow-up for outcome
started from AF onset date or matched cases’ AF onset date for the matched cohort.
Abbreviation: AF, Atrial fibrillation.
⁎ For each participant, only the outcome that occurred earliest was counted.
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compares the hazards of total cardiovascular disease
outcomes and all-cause mortality among individuals with
AF but no apparent comorbidities with typical AF and
separately with a matched cohort without AF. Compared
with typical AF, the AF without comorbidities group had a
33% lower hazard of all-cause mortality as well as 34% lower
hazard of total cardiovascular disease events. Supplementary
Table 5 demonstrates the comparison of individual cardio-
vascular disease outcome between groups. The AF without
comorbidities group had lower incidence of heart failure
(HR 0.52, P b .001). Compared with individuals with typical
AF, the incidence of stroke, and myocardial infarction were
not different significantly. In comparison with the matched
cohort without AF, however, AF without comorbidities had
significantly higher risk for all-cause mortality (HR 1.43, P b
.001), and total incident cardiovascular events (HR 1.73, P b
.001). The AF without comorbidities group had three-fold
higher risk for heart failure (HR 2.94, P b .001) than the
group without AF. However, the incidence of stroke, and
myocardial infarction were not significantly different.
We evaluated different factors associated with the
AF-related adverse clinical outcome in individuals with AF
without comorbidities in Supplementary Table 6. Among all
factors tested (e.g. sex, body mass index, systolic blood
pressure, warfarin use, antithrombotic use at the time of AF
diagnosis), most were not significantly associated with
clinical outcomes except for the age of AF onset. Lastly,
we developed corrected group prognostic curves for the
cumulative incidence of cardiovascular events in individuals
with AF without comorbidities, typical AF, and without AF,
adjusted by age, sex, and cohort in Figure 1. The typical AF
group showed the highest cumulative incidence of cardio-
vascular outcomes, followed by the AF without comorbid-
ities group, and the matching group without AF.
Discussion
We evaluated the epidemiology and clinical outcomes
of AF without recognized comorbidities, which has been
referred to as ‘lone AF’. We detected that AF without
comorbidities carried significantly higher risk of cardio-
vascular events and mortality compared with the match-
ing group without AF.
‘Lone AF’ receives special attention as it represents a
subset of AF without an apparent cause. However, as our
knowledge of subclinical cardiovascular disease and
pathophysiology of AF has expanded,7 there has been
tremendous variation in the definition of ‘lone AF’. Data
regarding the characteristics and clinical outcomes of
‘lone AF’ are conflicting and not amenable to a direct
comparison due to heterogeneity of study samples.
The prevalence of AF without comorbidities varies
from 0.2-11% depending on the definition of AF
used.3,5,15 In the 1980s, the Framingham Heart Study
reported that ‘lone AF’ comprised 11% of all individuals
with AF.5 However, the definition used in the prior
Table III. Comparison of cardiovascular outcomes in AF without comorbidities, typical AF and matching cohort without AF
AF without comorbidities vs.
typical AF (n = 1204)
AF without comorbidities vs.
matched no-AF (n = 1873)
Outcome HR (95% CI) P value HR (95% CI) P value
All-cause mortality 0.67 (0.55-0.81) b.001 1.43 (1.18-1.75) b.001
Total cardiovascular events 0.66 (0.55-0.80) b.001 1.73 (1.39-2.16) b.001
Abbreviations: AF, Atrial fibrillation; CI, confidence interval; HR, hazard ratio.
Figure 1
Individuals at 
risk, n
Year of follow up
0 2 4 6 8 10
AF without 
comorbidities
173 123 112 94 77 66
Typical AF 1031 658 493 356 265 183
Matched no-AF 1700 1605 1345 1140 928 785
Cumulative incidence of combined cardiovascular events (the earliest
of stroke, heart failure, myocardial infarction and death) in
individuals with AF without comorbidities, typical AF, and the
matching referents without AF adjusted by age, sex, and cohort,
accounting for the competing risk of non-cardiovascular death. For
the matched non-AF group the follow-up began at the diagnosis date
of matched AF without comorbidities.
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Framingham analysis was lenient compared with current-
ly accepted definitions and the investigators did not
exclude hypertension, or other concurrent medical
conditions or triggers. In the same decade, the propor-
tion of ‘lone AF’ over the period of 1950 to 1980, was
reported as 2.7% among residents in Olmsted County
using a stricter criteria.3 To define AF without comor-
bidities, the Olmsted investigators additionally excluded
individuals with coronary heart disease, valvular heart
disease, heart failure, cardiomyopathy, chronic obstruc-
tive pulmonary disease, ageN60 years at time of diagnosis,
and other triggers such as trauma, surgery, or acute
medical illness.3
Literature showed conflicting data regarding role of age
in ‘lone AF’ population. It is known that the incidence of
AF increases with increasing age, labeling AF “a disease of
the elderly”16 Some longitudinal studies incorporated the
age b60 years as definition of ‘lone AF’ based on this
observation. However, there is no pathophysiological
explanation for the age cut-off of 60 years. Rather, recent
literature questioned the value of age criteria by
demonstrating lack of significant atrial enlargement, AF
progression or short term prognosis in idiopathic AF
patients at advanced age.17 Presumably age limit was
used to ensure exclusion of any “unknown” causes of AF
or age-related AF onset. But Wyse et al. also points out age
limit of 60 years seems arbitrary and “excessively
conservative in the modern era”.18
In our current work, we performed the analysis
without using the age criteria given a small sample size.
Compared to the Olmsted county cohort, however, we
applied additional criteria such as ECG evidence of left
ventricular hypertrophy and prolonged PR interval,
obesity, hyperthyroidism, alcohol consumption, and
intense exercise via a thorough chart review. We
demonstrated that AF without comorbidities had an
overall prevalence of 1.7% or 0.3% with age b60 years in
our community-based cohort. Also we may speculate that
the incidence and prevalence of AF without comorbidities
would be even lower if data for comorbidities and
echocardiographic data were available for the entire cohort.
The clinical outcomes related to AF without comorbid-
ities conflict in the literature. Initially, it was thought to be
a benign condition with normal life expectancy especial-
ly if the diagnosis was made at younger age and in a
paroxysmal form.1,3,4 In contrast, other literature dem-
onstrated that AF, even in the absence of other
comorbidities, remains associated with higher mortality
and cardiovascular outcomes, with up to four-fold
increase in stroke, four-fold increase in cardiovascular
death rate, and 2-fold higher risk for overall adverse
cardiovascular outcomes than the general population
without AF.1,15 Considering that the literature did not
suggest a significant risk of heart failure among AF
without comorbidities,19,20 our finding of three-fold
increase in heart failure risk in this group, is interesting.
The higher risk for heart failure may be due to the older
mean age of our individuals with AF without comorbid-
ities compared with other studies as it is suggested in the
description of clinical outcomes in AF without comor-
bidities and age b60 years (Supplementary Table 4). In
contrary, the risk for stroke and myocardial infarction
were not significantly elevated.
Potpara et al. also suggested that ‘lone AF’ generally has
a favorable prognosis but long-term outcome was
influenced by the development of cardiovascular dis-
ease.19 Our analysis corroborated this notion by showing
that advancing age of AF onset was associated with
adverse clinical outcomes in AF without comorbidities. It
is possible that the cardiovascular outcomes associated
with AF without comorbidities is due to development of
other cardiovascular risk factors over time, or that AF
itself is the first manifestation of subclinical cardiovascu-
lar disease, or that it confers an increased risk of
cardiovascular events.21
Recently the question was raised if ‘lone AF’ exists at all.
With a significant advancement in detecting subclinical
cardiovascular disease and numerous emerging risk
factors for AF, some literature suggests that ‘lone AF’ is
a misnomer; these patients may have subclinical cardio-
vascular disease that is below the threshold of detection
as the development of cardiovascular disease takes place
over the years.7,22,23 We cannot directly answer the
question regarding the existence of ‘lone AF’ in this study.
We elucidated by using more contemporary definition,
however, that AF without recognized clinical comorbid-
ities, had worse clinical outcomes than individuals
without AF. Perhaps, the worse prognosis is due to the
possibility that even in the absence of structural heart
disease, AF may cause endothelial damage with altered
molecules such as E-selectin, von Willebrand factor, and
soluble thrombomodulin.24 However, whether AF in
itself increases the risk of cardiovascular outcomes or it is
a marker of emerging cardiovascular disease still remains
unclear. For this reason, ‘lone AF’ term is misleading as it
implies a benign condition. As such, if ‘lone AF’ is used,
providers should be aware of the potential adverse
outcomes of AF of any kind.
The main strengths of our study are the large
community-based sample, long follow-up period, and
systematic collection of AF, AF risk factors, cardiovascular
conditions, and outcomes. Our study has limitations,
mainly due to the community-based longitudinal design
and modest number of individuals with AF without
comorbidities. First, we did not use the age criteria (age
b60 years) for our analysis. However we would expect
that the age-related impact on the outcomes in our
comparative analysis between AF without comorbidities
and general population without AF would be nondiffer-
ential by using the matched cohort design. Second, we
did not investigate different patterns of AF such as
transient vs. paroxysmal vs. chronic AF due to imprecise
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ability to characterize suchpatternswithFHSdata. Therefore,
we were also unable to quantify the relation of burden and
duration of AF to clinical outcomes. Third, echocardiograph-
ic data and chronic obstructive pulmonary disease were
available for a subset of the AF individuals without
comorbidities (23% and ~50% respectively). We acknowl-
edge that we may have included individuals with subclinical
valvular heart disease, left atrial enlargement, or cardiomy-
opathy in our AF without comorbidities group. Fourth, we
did not match for cardiovascular risk factors in the non-AF
population to AF without comorbidities. The non-AF
population was matched only for age, sex and cohort in
order not to over-interpret our findings. Fifth, we may not
have accounted for all possible co-morbidities and triggers
despite a vigorous chart review. We could have missed the
risk factors thatwerebelow the thresholdof detection at time
of AF diagnosis or not have included all possible
co-morbidities that can be observed with AF in a terminal
stage of life.21 Sixth, we did not have sufficient data to
examine family history or genetic data in relation to our AF
classification. Our sample consisted of middle age and older
adults predominantly of European ancestry, limiting general-
izability to other ethnicities and younger individuals. We had
modest power to examine the relation of AF without
comorbidities vs. typical AF vs. without AF in relation to
specific cardiovascular events, and to examine the risk factors
for outcomes in individuals with AF without comorbidities.
Conclusions
‘Lone AF’ has been thought to be a benign condition.
However, our study confirmed that AF without clinically
apparent comorbidities carries a greater risk of total
cardiovascular outcomes and mortality than individuals
without AF. Thus one should use the term ‘lone AF’ with
caution and understand the potential adverse prognosis
of AF of any kind. Further research is indicated to address
the implication of AF without comorbidities, methodol-
ogy of follow-up, appropriate prognostication, assess-
ment of individual thromboembolic risk, AF-related
symptoms, rate vs. rhythm control, and anticoagulation
treatment strategies in this population.
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